Novavax aims for two billion COVID-19 vaccine doses: Expands deals with SII
Under an agreement with the Serum Institute of India (SII), Novavax is going to increase its potential COVID-19 vaccine production ability to two billion doses per year.
Novavax has signed a deal with the Serum Institute of India in August to produce the COVID-19 vaccine, for low- and also middle-income countries and India.
The Serum Institute of India will additionally manufacture the antigen component of the vaccine, dubbed NVX‑CoV2373, as part of the expanded contract. According to Novavax, it will certainly bring its production capacity to more than two billion doses by mid-next year.
Presently, Novavax’s vaccine is in mid-stage trials, and high levels of antibodies against COVID-19 was shown after early-stage research. The pharma firm prepares to start late-stage trials in the third quarter.
Novavax stated that it will provide 60 million dosages of its coronavirus vaccine prospect to the United Kingdom as early as the first quarter of next year.
Additionally, after the firm was granted $1.6 billion for its potential vaccine, the firm is preparing to provide 100 million doses to the United States by January and also has authorized supply arrangements with Japan and Canada.
Currently, various other drug manufacturers such as Pfizer and Moderna have started large late-stage studies of their speculative vaccines.
Novavax is a late-stage biotechnology firm that supports improved international health via the exploration, advancement, and commercialization of innovative vaccines for contagious infections.
They have greater than a decade of experience emulating some of the globe’s most devastating diseases, consisting of COVID-19, seasonal influenza, SARS, MERS, RSV, and Ebola. Significant breakthroughs and hard-won lessons reveal that their proven modern technology has remarkable capacity to make a substantial contribution to public health around the world.
Novavax aims for two billion COVID-19 vaccine doses: Expands deals with Serum
Author: Sruthi S